TELA Bio, Inc. (TELA) Shareholder/Analyst Call TranscriptSeeking Alpha · Oct 8, 2026
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue ReinforcementGlobeNewsWire · Oct 5, 2026
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in StockDefense World · Sep 21, 2026
TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head AnalysisDefense World · Sep 10, 2026
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction InitiativeGlobeNewsWire · Aug 31, 2026
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 11, 2026TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.17 | -$0.20 | Miss |
| May 12, 2026 | -$0.14 | -$0.21 | Miss |
| Mar 25, 2026 | -$0.18 | -$0.16 | Beat |
| Nov 13, 2025 | -$0.17 | -$0.19 | Miss |
| Aug 11, 2025 | -$0.18 | -$0.22 | Miss |
| May 8, 2025 | -$0.21 | -$0.25 | Miss |